The Secretary of State, in exercise of the powers conferred by section 7(4) of the Misuse of Drugs Act 1971(a), and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act, makes the following Order:

Citation, commencement and extent

1.—(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) (No. 2) (England, Wales and Scotland) Order 2017 and comes into force on the 27th November 2017.

(2) This Order extends to England and Wales and Scotland.

Amendment to the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015

2.—(1) The Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015(b) is amended as follows.

(2) In paragraph 1(a) of Part 1 of the Schedule after “Methylnaphthidate (HDMP-28)” insert—

“N-methyl-1-(thiophen-2-yl)propan-2-amine (methiopropamine or MPA)”.

Home Office
16th November 2017

Ben Wallace
Minister of State

(a) 1971 c. 38.
EXPLANATORY NOTE

(This note is not part of the Order)

Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 by inserting the drug known as methiopropamine or MPA into Part 1 of the Schedule to that Order.

A full impact assessment of the effect that this instrument will have on the costs of business and the voluntary sector is available and is published with the Explanatory Memorandum alongside the instrument on www.legislation.gov.uk.